drugset / Trial / NCT05955105
A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies
NaSingle-groupOpen-labelTreatment
Summary
This is a multicenter, open-label, phase Ib/IIa study. The first part of the study will evaluate the safety, tolerability and preliminary efficacy of ILB2109 and Toripalimab in patients with locally advanced or metastatic solid malignancies. The second part of the study will evaluate the efficacy of ILB2109 and Toripalimab in patients with selected advanced solid malignancies.
Timeline
- Start
- 2023-07-25
- Primary completion
- 2026-01-25
- Completion
- 2026-07-24
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ILB2109 | Unknown | — | Oral |
| Subject | Toripalimab | Monoclonal antibody | — | Intravenous |